Core Insights - The China International Import Expo (CIIE) serves as a significant platform for enhancing Swiss-Chinese economic and trade cooperation, acting as a "multiplier" for Swiss companies to expand in the Chinese market [1][3] - The Swiss Center has evolved into a key navigator for Swiss enterprises entering the Chinese market, helping over 100 companies participate in CIIE since its inception [2][3] Group 1: Swiss Center's Role - The Swiss Center has been a consistent participant in CIIE, helping Swiss companies, especially SMEs, showcase products and find business partners [2] - The Center has witnessed a growing recognition and satisfaction among Swiss enterprises regarding CIIE, with participation expanding from four companies in the first year to 24 companies in the seventh year [8][11] Group 2: Innovations and Developments - The Swiss Center has introduced a Business Development department to specifically support Swiss consumer goods companies, reflecting the increasing number of exhibitors at CIIE [6] - A new position, "Customer Success Manager," was created to assist Swiss companies in successfully entering the Chinese market, with a focus on reducing the product entry cycle from 12 months to 3 months [6][7] Group 3: Market Opportunities - CIIE provides Swiss brands with opportunities to test products, expand sales channels, and enter the Chinese market, leading to high participation enthusiasm among Swiss enterprises [11] - The introduction of an innovation incubation area at CIIE aims to meet the needs of Swiss startups looking to enter the Chinese market, showcasing 14 medical technology companies [11]

Core Viewpoint - Smith+Nephew has announced a strategic partnership with Standard Health to develop the first Orthopaedic Ambulatory Surgery Centre in the UK, aimed at improving access to advanced joint repair and replacement technologies for patients [1][2]. Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with annual sales of $5.8 billion in 2024 [9]. - Standard Health specializes in orthopaedic care and has provided NHS services since 2012, with plans for nationwide expansion [10]. Partnership Details - The new centre in Poole, Dorset, will cater to both NHS and private patients, offering procedures such as rotator cuff repair and knee replacements, and is expected to open in 2025 [1][3]. - Standard Health plans to open an additional 10 sites in the UK over the next three years, totaling 20 by 2030 [2]. Operational Model - The centre will adopt the Ambulatory Surgery Center (ASC) model from the US, which has proven benefits including increased procedural efficiency and high patient satisfaction rates [3][6]. - In the US, ASCs account for over 50% of all outpatient surgical procedures, with more than 6,000 facilities currently operating [3]. Market Demand - There are over 850,000 individuals waiting for orthopaedic surgery in the UK, highlighting the need for independent providers to meet this demand [3]. - The partnership aims to address the long wait times for procedures in the UK, providing a sustainable model for care [4]. Expected Benefits - The ASC model is associated with a 92% patient satisfaction rate and can reduce costs of joint replacements by 40% compared to hospital-based surgeries [6]. - The collaboration is expected to enhance the quality of care for patients and provide value for NHS commissioners [4].

Core Viewpoint - Brainlab AG, a medical technology company, has announced plans for an IPO on the Frankfurt Stock Exchange, aiming to raise up to €200 million to fund growth initiatives and strengthen its balance sheet and sales team [1] Company Summary - Brainlab is headquartered in Munich and focuses on developing software that enhances the precision, data-driven approach, and minimally invasive nature of surgical and cancer treatments [1] - The company also provides tools to help hospitals plan and guide medical procedures [1] Financial Summary - The IPO is expected to include secondary shares, although the announcement did not specify the number of shares to be issued [1] - The raised capital will be allocated towards growth plans, reinforcing the company's financial position and expanding its sales capabilities [1]

Core Viewpoint - The deadline for the award application for the Global MedTech Innovation Awards has been extended to June 20, 2025, to allow more time for participants to prepare and submit their materials, aiming to showcase innovations and contributions in the medical device field [1]. Group 1: Event Overview - The Global MedTech Conference 2024 will take place on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, with an expected attendance of around 500 participants from various sectors including government, hospitals, leading enterprises, startups, investment institutions, and research institutes [5]. - The conference will feature a main stage for showcasing and awarding global medical technology innovations [5]. Group 2: Award Categories - The awards to be presented include: 1. 2025 Global MedTech Innovation Award 2. 2025 Global MedTech Clinical Application Award 3. 2025 Global MedTech Service Contribution Award 4. 2025 Global MedTech Supply Chain Excellence Award 5. 2025 Global MedTech Innovation & Translation Award (Individual) [4][8]. Group 3: Application Process - The application phase is open from now until June 20, 2025, followed by a review phase from June 21 to June 29, with results to be announced between June 30 and July 4, and the awards to be presented on July 17, 2025 [12]. - Participants must fill out a specific form or send an email with required details to apply for the awards [13]. Group 4: Evaluation Criteria - The awards are aimed at various entities including medical device companies, healthcare institutions, and service providers, with criteria focusing on originality, advanced technology, clinical application, and industry impact [7][10][11]. - Specific standards are set for each award category, emphasizing the need for innovative products or technologies that demonstrate clear clinical efficacy and potential for widespread application [10][11]. Group 5: Conference Agenda - The conference will cover topics such as global medical technology development trends, research and transformation paths for imaging platforms, new consumables, brain-machine interfaces, interventional devices, diagnostic equipment, and the integration of AI in healthcare [6]. - It will also address capital market interests in technology directions and enterprise profiles, as well as overseas market access and marketing strategies [6].

Core Viewpoint - The article announces the extension of the application deadline for the Global MedTech Innovation Awards to June 20, 2025, to allow more time for participants to prepare their submissions and showcase their innovations in the medical technology field [1]. Group 1: Event Overview - The Global MedTech Conference 2024 will take place on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, with an expected attendance of around 500 participants from various sectors including government, hospitals, leading enterprises, startups, investment institutions, and research institutes [5]. - The conference aims to highlight and award groundbreaking achievements in medical technology, with a focus on innovation, application, and service contributions [4][8]. Group 2: Award Categories - The awards include: 1. 2025 Global MedTech Innovation Award 2. 2025 Global MedTech Clinical Application Award 3. 2025 Global MedTech Service Contribution Award 4. 2025 Global MedTech Supply Chain Excellence Award 5. 2025 Global MedTech Innovation & Translation Award (Individual) [4][8]. Group 3: Application Process - The application phase is open from now until June 20, 2025, followed by a review phase from June 21 to June 29, with results to be announced between June 30 and July 4 [11]. - Participants must submit specific documents including a personal resume, a summary of research achievements, and any relevant supporting materials [13].

Financial Data and Key Metrics Changes - The overall growth in the first quarter was 4.1%, with the pharmaceutical group growing by 4.2% and the med tech group by 4% [10] - The company has delivered consistent results, meeting or exceeding analyst expectations in earnings for 28 consecutive quarters over the past seven years [9] - The company has committed to a growth target of 5% to 7% from 2025 to 2030, with confidence in achieving this based on current results [11] Business Line Data and Key Metrics Changes - The pharmaceutical group showed a growth of 4.2% despite facing headwinds from biosimilars for its major product, Stellara [10] - The med tech group also reported a growth of 4%, indicating stability across both segments [10] - The company has invested $50 billion in M&A and R&D over the last two years, with an additional $55 billion planned for R&D manufacturing and technology in the U.S. over the next four years [11] Market Data and Key Metrics Changes - The company is optimistic about the biopharmaceutical and medical technology industries, citing significant medical innovation opportunities [5][22] - The U.S. market is seen as a key area for growth, with the administration's support for American businesses and manufacturing jobs [6] Company Strategy and Development Direction - Johnson & Johnson emphasizes its unique position as a healthcare company that spans the entire patient journey, with unmatched breadth in capabilities [7] - The company is focused on maintaining leadership in cardiac ablation and investing in new technologies to enhance its med tech offerings [56] - The strategy includes moving into higher growth markets, particularly in cardiovascular and robotics [85] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the industry despite macro uncertainties, highlighting a combination of headwinds and tailwinds [5][22] - The company is actively engaging with the administration to ensure continued innovation while making medicines affordable [23] - Management believes there are significant disconnects between market expectations and the company's potential, particularly in new product launches [12][14] Other Important Information - The company has a strong track record of dividend increases for 63 consecutive years, reflecting its financial stability [9] - The company is committed to improving gross margins and has various efficiency programs in place [51][54] Q&A Session Summary Question: How does the company view the current macro environment and its impact? - Management expressed optimism about the biopharmaceutical and medical technology industries, noting the potential for innovation despite uncertainties [22] Question: What is the company's strategy regarding drug pricing reforms? - Management highlighted the need for dialogue with the administration to balance innovation and affordability in medicines [24][30] Question: Can you provide an update on the talc litigation? - The company is back in the tort system and is confident in its position, having won 16 out of 17 cases related to ovarian cancer [37][38] Question: What are the expectations for financial performance in 2025? - The company is guiding for organic sales growth of 2% to 3% and EPS growth of 5% to 7%, with optimism about pharmaceutical product performance [43] Question: How does the company plan to address competitive pressures in the med tech space? - Management emphasized a commitment to innovation in cardiac ablation and plans to enhance its product offerings in electrophysiology [56][65]

当客户想要一些超出公司"核心能力"的新东西时，第一反应不要拒绝，而是说："行，我们能做。" 1 "问题导向，而不是产品导向" 在如今的大公司中，一切都围绕着产品进行。在美国的时候，我家用了好多年的汰渍有了些许变化。我和 家人都看出来了，这是来了一位新的产品经理，他们把洗衣粉蓝色的颗粒换成了绿色，然后称之为"全新升 级"。这是创新吗？我不太确定。 可口可乐发生了什么？除了经典可乐，他们后来还推出了健怡可乐、零度可乐、香草可乐和樱桃可乐等各 种可乐，同样，这算不算一种创新？我觉得不是， 对企业家来说，我们不关注产品，更关注问题 。 来源：TED官网截图 伦敦商学院创业教授约翰·马林斯（John Mullins）在之前的TED演讲中曾分享了几种"反传统"企业家思维。他认 为，在某些事情即将发生时，思维率先决定我们对其的反应。这些事情，就是企业家获得成功的机会。 在他看来，"行，我们能做""重视解决问题""思考聚焦一些""大胆要钱""很多东西可以借"这些"反传统"企业家思 维可以帮助创业者或企业家解决他们正面临的困难和挑战。 1 "行，我们能做" 商学院的入门战略是这么说的：我们在一家企业中该做的是"尽其所长"。我们 ...

Core Viewpoint - The medical technology industry is at a crossroads of breakthrough and reconstruction, with advancements in AI-assisted diagnosis, high-end intelligent diagnostic equipment, innovative medical materials, and regenerative medicine reshaping disease discovery, treatment, and management [1] Group 1: Conference Overview - The Second Global MedTech Conference will be held on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, aiming to promote the collaborative development of the global medical technology industry chain, innovation chain, and clinical application [1][4] - The first conference, Global MedTech Conference 2024, was organized by Siyu [2] Group 2: Awards and Recognition - The conference will present several awards to recognize breakthroughs in medical technology, including the 2025 Global MedTech Innovation Award and the 2025 Global MedTech Innovation Application Award [3][7] - The awards aim to honor cutting-edge technological advancements, successful results transformation, and outstanding services in the medical technology field [3] Group 3: Conference Agenda - Proposed agenda topics include analysis of global medical technology development trends and policy environments, research and transformation paths for imaging platforms, new consumables, brain-computer interfaces, interventional devices, and diagnostic equipment [5] - Other topics will cover experiences in the intersection of medicine and engineering, breakthroughs in AI-assisted diagnosis and digital therapy, and insights into technology directions and company profiles attracting domestic and foreign capital [5] Group 4: Participation and Submission Guidelines - The awards are open to medical device and digital medical technology companies with innovative products or platform technologies that demonstrate originality, advancement, and potential for large-scale industrialization [6] - Submission for the awards is open until May 31, 2025, with a review phase from June 1 to June 15, 2025, and results to be announced between June 16 and June 22, 2025 [10]

编辑丨王多鱼 排版丨水成文 光 在向生物传递大量外部信息方面起着尤为关键的作用，使生物能够理解世界。然而，哺乳动物只能感知 电磁波谱中很小一部分作为可见光，通常在 400-700 纳米的范围内。这意味着超过一半的太阳辐射能量以 红外线 （>700 纳米） 的形式存在，对哺乳动物来说是不可察觉的。 人眼所见光谱范围的局限是由视网膜感光细胞中的感光蛋白 （Opsin） 固有的物理化学特性所决定，这导 致了大量本可能获取到的感觉信息的缺失。尽管诸如夜视镜或红外光-可见光转换器之类的工具已被用于红 外探测，但它们需要额外的能量支持，并且通常无法区分多个光谱中的红外光信息。此外，每个红外光-可 见光转换器都需要多层结构，这使得它们不透明且难以与人眼集成。 2019 年， 薛天 团队等在 Cell 发表论文 【1】 ， 利用一种转换红外光成为可见光的上转换纳米材料，经特 殊修饰后注射到小鼠视网膜中，首次实现了哺乳动物的裸眼近红外 （NIR） 图像视觉能力。然而，由于手 术具有侵入性，这种方式显然不会被人们轻易接受。 因此， 通过非侵入性方式相对自由的调节人眼感光波谱范围， 甚至赋予人类近红外视觉能力，对人类而言 仍然至关 ...

Assertio Holdings (ASRT) Conference Summary Company Overview - Assertio Holdings is a specialty pharmaceuticals company with a market cap of approximately $70 million and shares trading at around 70¢ [2][4] - The company is focused on long-term growth and has a leadership team with extensive commercial experience in various therapeutic areas [5][6] Core Assets and Financial Performance - Assertio's core assets include Rovidone and SYMPAZAN, with Rovidone being a novel long-acting G-CSF approved in the last twenty years, targeting a market worth about $1 billion [8][9] - The company reported net sales of $26 million for the first quarter and maintains a positive adjusted EBITDA with a cash balance of nearly $90 million [9] - The financial outlook for the year includes projected net sales of $108 to $123 million and non-GAAP EBITDA of $10 to $20 million [10] Transformation and Growth Strategy - The company is in a transformation phase, simplifying its corporate structure and optimizing its asset portfolio, focusing on growth assets like Rovidone and SYMPAZAN [12][15] - Assertio aims to reduce legal exposure, which will allow for reinvestment into the business and positively impact EBITDA [13][14] - Business development is seen as a key enabler for future growth, with a focus on oncology, neurology, and rare diseases [14] Product Insights - Rovidone contributes over half of the total net sales and is expected to grow modestly this year, with plans to expand into the commercial segment by 2026 [19][21] - SYMPAZAN, an oral film formulation for Lennox Gastaut syndrome, is projected to grow to $13 million this year and has the potential to reach $25 million in the coming years [28] Competitive Landscape - The market for white blood cell stimulants is competitive, with Rovidone competing against biosimilars like Neulasta. Assertio is focused on managing average selling prices (ASP) smartly to sustain growth [23][24] Legal and Operational Improvements - Assertio has successfully reduced its litigation overhead, particularly related to opioid litigation, which has allowed for a cleaner balance sheet and operational focus [36][38] - The company has divested certain assets to streamline operations and eliminate legal distractions [38] Future Outlook - The CEO expressed optimism about the company's trajectory, aiming for significant growth and improved operational efficiency over the next year [41][42] - Assertio is positioned to explore mergers and acquisitions to enhance its portfolio, supported by a strong balance sheet with $40 million in convertible debt due in 2027 [34][35] Key Takeaways - Assertio is undergoing a transformation aimed at growth, with a focus on optimizing its asset portfolio and reducing legal distractions [12][15] - The company has a solid financial outlook and is strategically positioned to capitalize on growth opportunities in specialty pharmaceuticals [10][14] - Assertio's leadership is optimistic about future performance, with plans to enhance product offerings and expand market presence [41][42]